NEW YORK – Oppenheimer has initiated coverage of MDxHealth with an Outperform rating and a price target of €2 per share.
In a note to investors on Monday, analyst Kevin DeGeeter cited the investment bank's expectation that the US Centers for Medicare and Medicaid Services will likely issue a positive Local Coverage Determination in 2021 for the use of the company's SelectMDx prostate cancer diagnostic in men considering a biopsy for prostate cancer detection.